Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Atara | Rare Historical Photos

After Two FDA Rejections, Rare Lymphoma Cell Therapy Tab-Cel Is Resubmitted on a Study Design FDA Once Doubted

After two FDA rejections, tab-cel for a rare post-transplant lymphoma was resubmitted, raising questions about how consistently the FDA judges evidence.

Medical Daily · Oct 2

1 Penny Stock Where You Can Spend Less And Earn More

This tiny stock could soar more than 400%, according to Wall Street.

Barchart · Jun 4, 2024

Lōgōs Atara 650b gravel wheelset review: lightweight, bombproof and reasonably priced — what’s not to like?

With the Atara, Lōgōs puts customers first with serviceable, robust components in a competitively lightweight and affordable package

Cycling Weekly · Aug 23, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics

Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara's mesothelin-targeted allogeneic and autologous CAR-T assets, ATA3271 and ATA2271. The enrollment was paused in the Phase 1 trial of ATA2271 for mesothelioma after a patient death. The move followed a strategic review and asset-level prioritization.…

Benzinga · May 23, 2022

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG's (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors. ATA3271 leverages Atara's EBV T-cell platform and is currently in IND…

Benzinga · May 20, 2022

New hope for multiple sclerosis sufferers as scientists ‘reverse symptoms’ with cells transplant

Experts are still unsure exactly what triggers MS, which affects more than 130,000 people in the UK

The Independent UK · Apr 15, 2022

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Apr 5, 2022

Read news from The Economist, FT, and more,
with one subscription

Atara Biotherapeutics Shares Fall After Reporting Patient Death In ATA2271 Autologous CAR T Trial

Memorial Sloan Kettering Cancer Center's (MSK) has notified the FDA of a fatal serious adverse event (SAE) associated with a patien

Benzinga · Feb 18, 2022

Fujifilm To Buy Cell Therapy Plant From Atara For $100M

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)

Benzinga · Jan 27, 2022

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jan 27, 2022

Coverage From

People

AnneMarije Rook

124 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Memorial Sloan Kettering Cancer Center

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.